Revenue: As of FY2025 Q3, the actual value is USD 1.765 M, missing the estimate of USD 1.902 M.EPS: As of FY2025 Q3, the actual value is USD -0.69, beating the estimate of USD -0.7875.EBIT: As of FY2025 Q3, the actual value is USD -26.15 M.<h3>Segment Revenue</h3><ul><li>License and Other Revenue: $199,000 for the three months ended September 30, 2025, and $28,293,000 for the nine months ended September 30, 2025.</li><li>Product Revenue, Net: $1,566,000 for the three months ended September 30, 2025, and $4,252,000 for the nine months ended September 30, 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: - $29,815,000 for the three months ended September 30, 2025, and - $55,274,000 for the nine months ended September 30, 2025.</li><li>Total Operating Expenses: $29,274,000 for the three months ended September 30, 2025, and $95,729,000 for the nine months ended September 30, 2025.</li><li>Loss from Operations: - $27,509,000 for the three months ended September 30, 2025, and - $63,184,000 for the nine months ended September 30, 2025.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $70,091,000 for the nine months ended September 30, 2025.</li><li>Net Cash Provided by Financing Activities: $92,536,000 for the nine months ended September 30, 2025.</li></ul><h3>Unique Metrics</h3><ul><li>Change in Fair Value of Warrant Liability: - $676,000 for the three months ended September 30, 2025, and $12,796,000 for the nine months ended September 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focusing on advancing mavorixafor to treat patients with chronic neutropenia, with a strategic restructuring to support this focus, including a reduction in workforce and closure of the Vienna R&amp;D facility.</li><li>Non-Core Business: The company is no longer prioritizing investment in the WHIM indication as part of its long-term strategy to complete the 4WARD Phase 3 trial.</li><li>Priority: The company aims to decrease annual spending by $30 million to $35 million per year through strategic restructuring.</li></ul>

X4 Pharmaceuticals | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 1.765 M